Home » Expert Content » Biologics Development » A strategy to remove formulation development from the critical path

A strategy to remove formulation development from the critical path

Summary: Biopharmaceuticals tend to be highly unstable. Therefore, as the product development program progresses to phase 3 clinical stage, formulation development is required to ensure drug product quality and stability during manufacturing, storage, and clinical administration. During this Q&A, Dr. Jun Lu, Director, Analytical Development at Catalent discusses how Catalent utilizes automation, specifically the UNcle® platform*, during formulation development.

Click here to download article.

The UNcle® Platform is a registered trademark of Unchained Labs.

bars6